73.9% of American adults were affected by obesity or overweight in 2017-2018, and this number is on the rise. High dose GLP-1s have been the first medication class to show weight loss of up to 15-20% with acceptable safety and tolerability profiles.
Studies find less than 30% continuation on any anti-obesity medication at 1 year, but obesity is a chronic progressive disease.
When medications are stopped, weight increases to the level seen with lifestyle changes alone.
A weight reduction of 5% for individuals with a BMI > 40 would yield $34.9 B in annual savings in medical costs alone.
NanoPortal ensures continuous dosing with GLP-1, the most efficacious drug class in weight loss.
Extended duration means weight stays off longer and patients avoid additional dosing burdens.
NanoPortal insertion can be performed in a quick, outpatient procedure.